Anthony T. Reder to Immunosuppressive Agents
This is a "connection" page, showing publications Anthony T. Reder has written about Immunosuppressive Agents.
Connection Strength
2.181
-
Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics. 2021 07; 18(3):1650-1653.
Score: 0.553
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
Score: 0.538
-
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. CNS Drugs. 2016 Feb; 30(2):135-47.
Score: 0.377
-
Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring. Neurology. 2019 04 09; 92(15):696-697.
Score: 0.117
-
Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord. 2016 Sep; 9:158-62.
Score: 0.098
-
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
Score: 0.087
-
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
Score: 0.083
-
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul; 120(7):1432-9.
Score: 0.077
-
Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013 Jan; 131(1):103-7.
Score: 0.076
-
Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 Feb; 11(2):165-83.
Score: 0.066
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
Score: 0.039
-
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
Score: 0.034
-
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014 Sep; 3(5):629-38.
Score: 0.021
-
Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
Score: 0.015